CGP 79787D (PTK787/ZK222584), CGP 84738, NVP-AAC789, NVP-AAD777 and related 1-anilino-(4-pyridylmethyl)phthalazines as inhibitors of VEGF- and bFGF-induced angiogenesis

Drugs of the Future

Volumn 27, Issue 1, 2002, Pages 43-55

  Bold, Guido ^a   Frei, Jörg ^a   Furet, Pascal ^a   Manley, Paul W ^a   Brüggen, Josef ^a   Cozens, Robert ^a   Ferrari, Stefano ^a   Hofmann, Francesco ^a   Martiny Baron, Georg ^a   Mestan, Jürgen ^a   Meyer, Thomas ^a   Wood, Jeanette M ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; CELL RECEPTOR; CGP 84738; CYTOKINE; GROWTH FACTOR RECEPTOR; IMATINIB; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; NVP AAC789; NVP AAD777; PD 173074; PHTHALAZINE DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VATALANIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; AUTOPHOSPHORYLATION; BLOOD VESSEL PERMEABILITY; CELL SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; ENDOTHELIUM CELL; HUMAN; MOUSE; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

EID: 0036125150     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2002.027.01.647609     Document Type: Review

References (67)

1. Receptor tyrosine kinases as targets for inhibition of angiogenesis
2. Molecular angiogenesis
3. Vascular permeability factor (VPF, VEGF) in tumor biology
4. Vascular endothelial growth factor (VEGF) and its receptors
5. Flk-1 as a target for tumor growth inhibition
6. The role of vascular endothelial growth factor in pathological angiogenesis
7. Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis
8. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
9. Clinical applications of angiogenic growth factors and their inhibitors
10. Anti-angiogenesis: New concept for therapy of solid tumors
11. What is the evidence that tumors are angiogenesis dependent?
12. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
13. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation
14. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
15. A cancer therapy resistant to resistance
16. Fighting cancer by attacking its blood supply
17. Angiogenesis as a target for tumor treatment
18. Angiogenesis inhibitors as cancer therapy
19. Angiogenesis and anti-angiogenesis: Perspectives for the treatment of solid tumors
20. Tumor angiogenesis: Past, present and the near future
21. Angiogenesis-Research frontiers. A basic science conference of the New York Academy of Medicine
22. Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis
23. Mechanisms of angiogenesis in vascular disorders: Potential therapeutic targets
24. Tumor angiogenesis as a therapeutic target
25. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosinekinase inhibitors
26. Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor
27. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
28. Phase lb trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data
29. Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors
30. The structure-based design of ATP-site directed protein kinase inhibitors
31. Growth factor receptor kinase inhibitors: Recent progress and clinical impact
32. Tyrosine kinase inhibitors: From rational design to clinical trials
33. Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases
34. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
35. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases
36. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
37. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
38. Identification of substituted 3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases
39. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors
40. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
41. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
42. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: Implications for combination treatment with photodynamic therapy
43. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis
44. Receptor proteintyrosine kinases and their signal transduction pathways
45. Signaling pathways induced by vascular endothelial growth factor
46. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3
47. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis
48. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics
49. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
50. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
51. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
52. Phase I dose escalation, pharmacokinetic (pk) study of a novel vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK222584 (PTK/ZK)
53. A study of the chemistry of pyrophthalone and related compounds
54. β-dicéto énamines hétérocycliques: 1. Indanediones-1,3 substitutées en 2 par un hétérocycle azoté
55. Synthesis of 4-arylamino-1H-pyrazolo[3,4-d]pyrimidines
56. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism
57. Structure of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
58. Fibroblast growth factors are required for efficient tumor angiogenesis
59. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model
60. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases
61. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation
62. Angiogenese und angiogenesehemmung im auge
63. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization
64. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis
65. Angiogenesis: Implications for rheumatoid arthritis